Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Follow-Up Questions
Unicycive Therapeutics Inc 的 CEO 是誰？
Dr. Shalabh Gupta 是 Unicycive Therapeutics Inc 的 Chairman of the Board，自 2016 加入公司。
UNCY 股票的價格表現如何？
UNCY 的當前價格為 $4.08，在上個交易日 decreased 了 0.24%。
Unicycive Therapeutics Inc 的主要業務主題或行業是什麼？
Unicycive Therapeutics Inc 屬於 Biotechnology 行業，該板塊是 Health Care
